Experimental shot takes aim at stomach cancer spread

NCT ID NCT07658196

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a drug called ACM-CpG, which is injected directly into the abdomen to stimulate the immune system against cancer. It includes 24 adults with colorectal or appendix cancer that has spread to the lining of the abdomen or caused fluid buildup. The main goal is to find a safe dose and see if it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ACM-CpG (a drug that stimulates the immune system)
What this could lead to
If it works, this could point toward a new treatment option for cancers that have spread to the abdomen.
What could go wrong
This is a very early phase 1 trial with only 24 people, so it is mainly checking safety and dosing. The drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPENDICEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rhode Island and the Miriam Hospitals (Brown University Health)

    Providence, Rhode Island, 02903/02906, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.